Targeting glycogen synthase kinase-3 in Alzheimer's disease

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 4, 2006, Pages 613-619

  Huang, Hui Chuan ^a   O'Brien, W Timothy ^a   Klein, Peter S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; 3 (INDOL 3 YL) 4 (1H INDAZOL 3 YL)MALEIMIDE DERIVATIVE; 6 BROMOINDIRUBIN; 6 BROMOINDIRUBIN 3' OXIME; AMYLOID BETA PROTEIN; AR A 014418; CHINESE DRUG; CHIR 98023; CHIR 99021; DANGGUI LONGHUI WAN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; INDIRUBIN; INDOLEMALEIMIDE DERIVATIVE; LITHIUM; LITHIUM ACETATE; LITHIUM CARBONATE; LITHIUM CHLORIDE; NP 031112; PAULLONE DERIVATIVE; RUTHENIUM; TAU PROTEIN; THIADIAZOLIDINONE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; WNT PROTEIN;

ALZHEIMER DISEASE; APOPTOSIS; BIPOLAR DISORDER; BLOOD BRAIN BARRIER; CELL SURVIVAL; CLINICAL TRIAL; CONCENTRATION RESPONSE; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENETIC CODE; HEART ARRHYTHMIA; HUMAN; LEUKOCYTOSIS; NEPHROGENIC DIABETES INSIPIDUS; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; NEUROFIBRILLARY TANGLE; NEUROMUSCULAR DISEASE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; SIDE EFFECT; THYROID DISEASE; TREMOR; WEIGHT GAIN;

EID: 33846181973     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.10.020     Document Type: Review

References (40)

1. LaFerla F.M., and Oddo S. Alzheimer's disease: abeta, tau and synaptic dysfunction. Trends Mol. Med. 11 (2005) 170-176
2. Balaraman Y., et al. Glycogen synthase kinase 3beta and Alzheimer's disease: pathophysiological and therapeutic significance. Cell Mol. Life Sci. 63 (2006) 1226-1235
3. Huang H.C., and Klein P.S. Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease. Curr. Drug Targets 7 (2006) 1389-1397
4. Phiel C.J., et al. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423 (2003) 435-439
5. Ryder J., et al. Divergent roles of GSK3 and CDK5 in APP processing. Biochem. Biophys. Res. Commun. 312 (2003) 922-929
6. Sun X., et al. Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci. Lett. 321 (2002) 61-64
7. Takashima A., et al. Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta. Neurosci. Lett. 203 (1996) 33-36
8. Chuang D.M. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases?. Crit. Rev. Neurobiol. 16 (2004) 83-90
9. Jope R.S., and Bijur G.N. Mood stabilizers, glycogen synthase kinase-3beta and cell survival. Mol. Psychiatry 7 Suppl 1 (2002) S35-S45
10. Gurvich N., and Klein P.S. Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol. Ther. 96 (2002) 45-66
11. McManus E.J., et al. Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J. 24 (2005) 1571-1583
12. Meijer L., et al. Pharmacological inhibitors of glycogen synthase kinase 3. Trends in Pharmacological Sciences 25 (2004) 471-480
13. Martinez A., et al. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev. 22 (2002) 373-384
14. Klein P.S., and Melton D.A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U S A 93 (1996) 8455-8459
15. Stambolic V., et al. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr. Biol. 6 (1996) 1664-1668
16. Jope R.S. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol. Sci. 24 (2003) 441-443
17. Zhang F., et al. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J. Biol. Chem. 278 (2003) 33067-33077
18. Williams D.S., et al. Switching on a signaling pathway with an organoruthenium complex. Angew Chem. Int. Ed. Engl. 44 (2005) 1984-1987
19. Kozikowski A.P., et al. Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease. Chem. Med. Chem. 1 (2006) 256-266
20. Meijer L., et al. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem. Biol. 10 (2003) 1255-1266
21. Hongisto V., et al. Lithium blocks the c-Jun stress response and protects neurons via its action on glycogen synthase kinase 3. Mol. Cel. Biol. 23 (2003) 6027-6036
22. Ring D.B., et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 52 (2003) 588-595
23. Noble W., et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. U S A 102 (2005) 6990-6995
24. Gould T.D., et al. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int. J. Neuropsychopharmacol. 7 (2004) 387-390
25. Plotkin B., et al. Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J. Pharmacol. Exp. Ther. 305 (2003) 974-980
26. Frame S., et al. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell 7 (2001) 1321-1327
27. De Sarno P., et al. Regulation of Akt and glycogen synthase kinase-3beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43 (2002) 1158-1164
28. Engel T., et al. Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J. Neurosci. 26 (2006) 5083-5090
29. Munoz-Montano J.R., et al. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett. 411 (1997) 183-188
30. Takashima A., et al. Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proc. Natl. Acad. Sci. U S A 95 (1998) 9637-9641
31. Kang D.E., et al. Presenilin couples the paired phosphorylation of beta-catenin independent of axin: implications for beta-catenin activation in tumorigenesis. Cell 110 (2002) 751-762
32. Forlenza O.V., et al. Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons. J. Neural Transm. 107 (2000) 1201-1212
33. Alvarez G., et al. Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord. 4 (2002) 153-165
34. Chen G., et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J. Neurochem. 72 (1999) 879-882
35. Lie D.C., et al. Wnt signalling regulates adult hippocampal neurogenesis. Nature 437 (2005) 1370-1375
36. O'Brien W.T., et al. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J. Neurosci. 24 (2004) 6791-6798
37. Beaulieu J.M., et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. U S A 101 (2004) 5099-5104
38. Kaidanovich-Beilin O., et al. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol. Psychiatry 55 (2004) 781-784
39. De Ferrari G.V., et al. Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol. Psychiatry 8 (2003) 195-208
40. Cohen Y., et al. Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment. Med. Oncol. 15 (1998) 32-36